000			01590nam a2200157 4500
008			250214b |||||||| |||| 00| 0 eng d
082			_bP.7-22
100			_aPhool Chandra
245			_aPHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF ALZHEIMER'S DISEASE
300			_aP.7-22
520			_aCognitive decline with aging is a concern, particularly in neurodegenerative and mental diseases. Cognitive enhancers focus on cholinergic and monoaminergic systems, but Phosphodiesterases (PDEs) have gained interest in enhancing cognition by increasing intracellular accessibility of additional messengers. The present study sought to elucidate the effects of PDE-Inhibitors on perception, feasible underlying mechanisms, and their application to existing hypotheses regarding the formation of memories. The review examines literature from 2010-2023 on the effects of various PDE medications on mental processes, including studies on PDE-Is and their relation to blood flow, euphoria, and long-term potentiation. PDE inhibitors enhance brain information processing, concentration, memory, executive function and memory use, likely due to an LTP-interrelated mode of action. PDE2-Is and PDE9-Is are potential candidates for cognitive enhancement, but isoform-specific PDE-Is with minimal negative properties are needed to realize their potential fully.
654			_aPDE inhibitors _asildenafil _acognition _acAMP _acGMP _amemory
700			_aHimanshu Sharma
773	0		_0125265 _9109909 _dMumbai Indian Drugs Manufacturer's Association _tIndian Drugs _x0019-462X
942			_cJA
999			_c131122 _d131122